ReviewThe Journal of allergy and clinical immunology2019
Pruritus in allergy and immunology.
Review in The Journal of allergy and clinical immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it, 109 citations in OpenAlex.
- IL-31 Inhibition as a Therapeutic Approach for the Management of Chronic Pruritic Dermatoses.Drugs · 2021Pooled it
- Dupilumab in Difficult-to-treat Chronic Spontaneous Urticaria: A Real-world Multicentre Cohort Study.Acta dermato-venereologica · 2026Observational
- Efficacy of Lebrikizumab on Pruritus: A Narrative Review.Advances in therapy · 2026Review
- The neuro-immune insights of itch: peripheral mechanisms and central glial contributions.Cellular & molecular biology letters · 2026Review
- Topical regimens for the management of uremic pruritus.Frontiers in medicine · 2026Review
- Case Report: Differential response to IL-13 inhibition: lebrikizumab following primary tralokinumab failure in atopic dermatitis.Frontiers in medicine · 2026Article
- PLA2G2F/lysoplasmalogen axis links epidermal lipid metabolism to type 2 inflammation and itch in atopic dermatitis.Frontiers in immunology · 2026Article
- Itching, Ionic Channels, Immune System, Magnesium and Antioxidants.Clinical, cosmetic and investigational dermatology · 2026Review
- Electroacupuncture exerts antipruritic and anti-inflammatory effects on atopic dermatitis by activating CB2 receptor.Chinese medicine · 2025Article
- Beyond the itch: the complex interplay of immune, neurological, and psychological factors in chronic urticaria.Journal of neuroinflammation · 2025Review
- Characterization of Mucosal Immune-Related lncRNAs and mRNAs in a Mouse Model of Allergic Conjunctivitis.Journal of inflammation research · 2025Article
- Soothing the Itch: The Role of Medicinal Plants in Alleviating Pruritus in Palliative Care.Plants (Basel, Switzerland) · 2024Review
- Review
- Antibacterial and Antiallergic Effects of Three Tea Extracts on Histamine-Induced Dermatitis.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Mantle Cell Lymphoma and Exaggerated Mosquito Bite Reactions: A New Perspective on Treatment Options.The Journal of clinical and aesthetic dermatology · 2024Article
- Neuroimmune interplay during type 2 inflammation: Symptoms, mechanisms, and therapeutic targets in atopic diseases.The Journal of allergy and clinical immunology · 2024Review
- Mast cell-sensory neuron crosstalk in allergic diseases.The Journal of allergy and clinical immunology · 2024Review
- Treatment of rosacea with upadacitinib and abrocitinib: case report and review of evidence for Janus kinase inhibition in rosacea.Frontiers in immunology · 2024Review
- Immunomodulatory potential of primary cilia in the skin.Frontiers in immunology · 2024Review
- Human placental extract suppresses mast cell activation and induces mast cell apoptosis.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Although evolutionarily conserved to expel ectoparasites and aid in the clearance of toxins and noxious environmental stimuli from the host, the type 2 immune response can become pathologic in the setting of a variety of allergic disorders. Itch can be a behavioral extension of type 2 immunity by evoking scratching and, in the setting of disease, can become chronic and thus highly pathologic as well. Classically, our understanding of itch mechanisms has centered around the canonical IgE-mast cell-histamine axis. However, therapies aimed at blocking the histaminergic itch pathway have been largely ineffective, suggesting the existence of nonhistaminergic itch pathways. Indeed, recent advances in itch biology have provided critical new insight into a variety of novel therapeutic avenues for chronic itch in the setting of a number of allergic disorders. Here we highlight how these new developments will likely inform the problem of pruritus in a variety of well-established and emerging conditions in the field of allergy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.